Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.60 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.60 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.60 |
| ▸ | BTK | Q06187 | 7/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | SGK1 | O00141 | 1/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129580 | 0.90 | NTRK1 (0.61) | BTKTNIKNTRK1KITRIPK1 | |
| SCHEMBL18129686 | 0.89 | SGK1 (0.61) | CLK1DYRK1ADYRK2DYRK1BBTK | |
| SCHEMBL18129529 | 0.89 | DYRK1A (0.55) | CLK1DYRK1ADYRK2DYRK1BBTK | |
| SCHEMBL18129733 | 0.88 | CLK1 (0.55) | CLK1DYRK1ADYRK2DYRK1BBTK | |
| SCHEMBL18129706 | 0.85 | CAMKK2 (0.50) | CLK1DYRK1ADYRK2DYRK1BBTK | |
| SCHEMBL18129616 | 0.85 | SGK1 (0.63) | DYRK1ABTKSGK1MAP3K11 | |
| SCHEMBL18129516 | 0.84 | BTK (0.51) | BTKTNIKSGK1MAP3K11KIT | |
| SCHEMBL18129654 | 0.84 | BTK (0.46) | CLK1DYRK1ADYRK2DYRK1BBTK | |
| SCHEMBL18129685 | 0.83 | MAP4K1 (0.48) | CLK1DYRK1ADYRK2DYRK1BBTK | |
| SCHEMBL18129741 | 0.83 | MAP3K11 (0.50) | DYRK1ABTKSGK1MAP3K11KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-03-26 | — | — | US | disclosed |
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297815-A1 | 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TANK, NFKBIA, TBK1 | CLK1 2500/4885DYRK1A 1134/4885DYRK2 794/4885 |
| US-10239873-B2 | 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same | NFKBIA, TANK, TBK1 | CLK1 2239/4885DYRK1A 1148/4885DYRK2 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.